Revised SPC: Nexplanon (etonogestrel) 68 mg implant for subdermal use

Source:
electronic Medicines Compendium - eMC
Publisher:
electronic Medicines compendium
Publication date:
16 January 2020

Abstract

SPC updated to include post market surveillance reports of undesirable effects from treatment including; respiratory disorders (e.g. cough and haemoptysis) and haematoma following insertion or removal of the implant.